Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Gilead Sciences to purchase CGI Pharmaceuticals

Gilead Sciences to purchase CGI Pharmaceuticals

28th June 2010

Gilead Sciences has agreed a deal to purchase CGI Pharmaceuticals, a privately-held healthcare firm which specialises in small molecule chemistry and kinase biology.

The firm has developed a range of small molecule kinase inhibitors, which Gilead believes could have potential applications in treating inflammatory conditions such as rheumatoid arthritis.

As a result, it will be paying up to a total of $120 million (79.7 million pounds) to make CGI a wholly-owned Gilead subsidiary, with the takeover set to be concluded at some point during the third quarter of 2010.

Dr Norbert Bischofberger, Gilead’s executive vice-president of research and development and chief scientific officer, said CGI’s “scientific leadership” represents a strong fit with Gilead’s research interests.

He added: “The acquisition of CGI represents a unique opportunity to expand our research efforts in an interesting and promising area of drug discovery.”

Last week, Gilead published new phase III clinical trial results for Cayston, an inhalation-based treatment for sufferers of cystic fibrosis.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.